Single Agent Armodafinil for Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01330446 |
Recruitment Status :
Active, not recruiting
First Posted : April 7, 2011
Last Update Posted : April 27, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Head And Neck Cancer Fatigue | Drug: Armodafinil Other: Placebo Behavioral: Questionnaires | Phase 1 Phase 2 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 26 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Armodafinil for Persistent Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer: a Randomized Phase II Study |
Actual Study Start Date : | May 19, 2011 |
Estimated Primary Completion Date : | November 1, 2022 |
Estimated Study Completion Date : | November 1, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Armodafinil
50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
|
Drug: Armodafinil
50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
Other Name: Nuvigil Behavioral: Questionnaires Series of questionnaires completed at different time points before, during, and at study completion.
Other Name: Surveys |
Placebo Comparator: Placebo
1 Placebo by mouth every morning for a 28 day cycle.
|
Other: Placebo
1 by mouth every morning for a 28 day cycle.
Other Name: Sugar Pill Behavioral: Questionnaires Series of questionnaires completed at different time points before, during, and at study completion.
Other Name: Surveys |
- Combined Patient-Reported Fatigue Scores [ Time Frame: 4-6 weeks ]Combined 4-week area under the curve (AUC) for the patient-reported "fatigue at its worst" item from the Brief Fatigue Inventory - BFI using a 0 (no fatigue) to 10 scale (worst fatigue).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients who were treated with either definitive or postoperative radiation or chemoradiation therapy for HNC with moderate to severe levels of patient reported fatigue, at 6 or more weeks after completing all planned cancer therapy. Patients who rated their fatigue level at 5 or greater on a 0 to 10 scale during any follow-up clinic visits at MD Anderson.
- Male and female patients >= 18 years old.
- Patients who speak English (due to the novel research and its complexity, we are only accruing English-speaking patients to the protocol).
- Patients must agree to discontinue any current herbal supplement use, and refrain from taking any herbal supplement while on protocol.
- Patients must be willing and able to review and understand informed consent documents and to provide written consent.
- Women of childbearing potential (women who are not postmenopausal for at least 1 year and are not surgically sterile) must have a negative urine pregnancy test.
- Sexually active males and females must agree to use effective birth control or to be abstinent for the duration of the study period.
- Women currently taking birth control pills or planning to start birth control pills must agree to an additional method of birth control (either abstinence or a barrier method) while on the study medication and for 1 additional month after study completion.
Exclusion Criteria:
- Patients who rated their fatigue level at 4 or less over the past 24 hours based on the fatigue at its worst item of the BFI.
- Patients with clinical evidence of active persistent cancer or progressive disease after completing planned cancer therapy, or with active recurrent cancer.
- Patients with potential medical or other underlying causes of fatigue, as determined by the treating physician or PI
- Patients with Hb <10.5 g/dL within previous 2 weeks.
- Patients with untreated or uncontrolled hypothyroidism, or TSH > ULN or free T4 < lower level of normal within previous 2 weeks.
- Patients with underlying cardiac or pulmonary disease resulting in dyspnea, hypoxia, or hypercapnia.
- Patients with a Karnofsky performance status <70
- Patients less than 18 years old
- Patients who are enrolled and receiving active treatment in other symptom intervention trials or who are in the treatment phase of another clinical trial
- Patients with pre-existing psychosis or bipolar disorder
- Patients with pre-existing renal impairment, as evidenced by serum creatinine > ULN on the most recent blood work, done at least within the previous 2 weeks.
- Patients with pre-existing cirrhosis or hepatic impairment or with abnormal liver function test as evidenced by total bilirubin > 1.5 x ULN or 2 times the upper limit of normal of alkaline phosphatase (ALP), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) on the most recent blood work, done at least within the previous 2 weeks.
- Patients with pre-existing Tourette's syndrome
- Patients who have used monoamine oxidase (MAO inhibitors) within the past 14 days
- Patients undergoing abrupt discontinuation of ethanol or sedatives (including benzodiazepines)
- Patients currently taking, or having taken within the previous 1 month, armodafinil, modafinil, amphetamine, or methylphenidate
- Patients on anticoagulants (i.e. warfarin, coumadin, or heparin) or clopidogrel
- Patients with a history of clinically significant cutaneous drug reaction, or a history of clinically significant hypersensitivity reaction, including multiple allergies or drug reactions
- Patients with a history of angina or cardiac ischemia, a recent history of myocardial infarction (within the past 1 year) or left ventricular hypertrophy, or patients with mitral valve prolapse
- Patients with uncontrolled hypertension or tachycardia, as determined by treating physician
- Patients who are pregnant, breastfeeding, or planning to become pregnant during the study period and for 1 month after stopping the study drug.
- Female patients who are currently on birth control pills as primary means of contraception, but are not willing to seek an additional effective method of contraception (such as barrier method) during the study period and for 1 month after stopping the study drug.
- Patients with a history of CNS stimulant abuse, such as methylphenidate, dextroamphetamine, or modafinil.
- Patients with major depressive disorder or severe depression (a score of 13 or greater on the BDI Fast Screen (BDI-FS). If this is the case, we will notify their treating physician for appropriate management or referral.
- Patients with current or a history of suicidal ideation.
- Patients currently taking midazolam, cyclosporine, ethinyl estradiol, or triazolam
- Patients currently taking carbamazepine, phenobarbital, rifampin, aminoglutethimide, nafcillin, nevirapine, phenytoin, azole antifungals, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, telithromycin, or verapamil
- Patients currently taking omeprazole, diazepam, propanolol, chlomipramine (or other tricyclic antidepressants), citalopram, methsuximide, or sertraline.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01330446
United States, Texas | |
Lyndon B. Johnson General Hospital | |
Houston, Texas, United States, 77026 | |
University of Texas MD Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Gary B. Gunn, MD | M.D. Anderson Cancer Center |
Responsible Party: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT01330446 |
Other Study ID Numbers: |
2010-0557 R01 026582-26 ( Other Grant/Funding Number: National Cancer Institute ) NCI-2011-00881 ( Registry Identifier: NCI CTRP ) |
First Posted: | April 7, 2011 Key Record Dates |
Last Update Posted: | April 27, 2022 |
Last Verified: | April 2022 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Head and Neck Cancer HNC Fatigue Patient-Reported Fatigue Fatigue-Symptom Intervention Postoperative Radiation Therapy Postoperative Chemoradiation Therapy |
Armodafinil Nuvigil Placebo Sugar Pill Questionnaires Surveys |
Head and Neck Neoplasms Fatigue Neoplasms by Site Neoplasms Modafinil Central Nervous System Stimulants |
Physiological Effects of Drugs Wakefulness-Promoting Agents Cytochrome P-450 CYP3A Inducers Cytochrome P-450 Enzyme Inducers Molecular Mechanisms of Pharmacological Action |